Equity · Healthcare
RGEN
NASDAQRepligen (RGEN)
The line runs 192 USD on 30 September through 168.52 USD on 5 November, on a scale from 160 to 200. Days the market did not trade hold the previous close, flat.
- Market cap
- 10.8B USD
- Revenue, year to Dec 2025
- 738.3M USD
- EPS, diluted, year to Dec 2025
- 0.86 USD
- 52-week range
- 102.85 USD – 192 USD
- Avg volume
- 108.0K
as of Nov 5, 2026
Have Repligen (RGEN) insiders bought or sold shares recently?
In the 90 days to 9 Nov 2026, Repligen insiders reported 5 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 12 Nov 2025, show no open-market purchase.
Form 4, 90 days to 9 Nov 2026, newest reported trade 5 Oct 2026
Buys 0Sells 5Net sold $5.95MOther filings 9
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 05 Oct 2026 | Loeillot OlivierChief Executive Officer | Sell | 5,535 | 1.0M USD |
| 24 Sep 2026 | Loeillot OlivierChief Executive Officer | Sell | 12,946 | 2.5M USD |
| 21 Sep 2026 | Loeillot OlivierChief Executive Officer | Sell | 5,426 | 977K USD |
| 04 Sep 2026 | Loeillot OlivierChief Executive Officer | Sell | 3,035 | 504K USD |
| 20 Aug 2026 | Loeillot OlivierChief Executive Officer | Sell | 5,426 | 977K USD |
| Sold | 5 open-market sales | 32,368 | $5.95M |
9 other filings in the window: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 06 Oct 2026 | Douglass Brian RobbCHIEF PRODUCT OFFICER | Award | 700 | |
| 05 Oct 2026 | Loeillot OlivierChief Executive Officer | Option exercise | 4,202 | 651K USD |
| 02 Oct 2026 | Loeillot OlivierChief Executive Officer | Tax withheld | 1,248 | 227K USD |
| 25 Sep 2026 | Garland Jason KCFO | Tax withheld | 421 | 80K USD |
| 24 Sep 2026 | Loeillot OlivierChief Executive Officer | Option exercise | 12,946 | 2.0M USD |
| 21 Sep 2026 | Loeillot OlivierChief Executive Officer | Option exercise | 5,426 | 769K USD |
| 03 Sep 2026 | Loeillot OlivierChief Executive Officer | Tax withheld | 2,842 | 482K USD |
| 01 Sep 2026 | Hughes ViolettaCHIEF ACCOUNTING OFFICER | Tax withheld | 277 | 47K USD |
| 20 Aug 2026 | Loeillot OlivierChief Executive Officer | Option exercise | 5,426 | 769K USD |
Which funds hold Repligen (RGEN)?
11 of the 45 institutional funds we track reported a Repligen position for the quarter ended 30 Jun 2026 — a combined 462.6M USD; the latest of those filings landed 02 Sep 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Maverick Capital | Added | 1,984,554 | 270.8M USD | +30.7% |
| Citadel Advisors | Trimmed | 376,309 | 51.3M USD | −65.8% |
| Balyasny Asset Management | Added | 355,507 | 48.5M USD | +183.3% |
| Marshall Wace | New position | 282,107 | 38.5M USD | |
| Point72 Asset Management | Trimmed | 166,157 | 22.7M USD | −70.8% |
| D. E. Shaw & Co. | New position | 83,328 | 11.4M USD | |
| Duquesne Family Office | New position | 77,400 | 10.6M USD | |
| Tudor Investment Corp | New position | 25,678 | 3.5M USD | |
| Man Group | Added | 20,341 | 2.8M USD | +81.9% |
| Two Sigma Investments | New position | 9,901 | 1.4M USD |
Showing the 10 largest of 11 reported positions. The figures above count all of them.
Have members of Congress traded Repligen (RGEN)?
The most recent congressional trade disclosed in Repligen is a sale by Lisa C. McClain (house, MI), dated 31 Oct 2025.
STOCK Act disclosures
| Traded | Member | Type | Amount | Filed after |
|---|---|---|---|---|
| 31 Oct 2025 | Lisa C. McClainhouse · Republican–MI | Sale | 1K USD–15K USD | 21 days |
| 30 Oct 2025 | Lisa C. McClainhouse · Republican–MI | Sale | 1K USD–15K USD | 22 days |
| 30 Oct 2025 | Lisa C. McClainhouse · Republican–MI | Purchase | 1K USD–15K USD | 22 days |
| 22 Jul 2025 | Lisa C. McClainhouse · Republican–MI | Purchase | 1K USD–15K USD | 22 days |
| 17 Jun 2025 | Lisa C. McClainhouse · Republican–MI | Sale | 1K USD–15K USD | 57 days |
| 11 Jun 2025 | Lisa C. McClainhouse · Republican–MI | Purchase | 1K USD–15K USD | 63 days |
What has been filed or recorded for Repligen (RGEN)?
The filings we hold for Repligen, newest first: 5 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 09 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 09 Oct 2026 | Fails to deliver | Shares failed to deliver | 413 shares | 68K USD notional · 0.001% of shares out |
| 08 Oct 2026 | Fails to deliver | Shares failed to deliver | 4 shares | 669 USD notional · <0.001% of shares out |
| 01 Oct 2026 | Fails to deliver | Shares failed to deliver | 551 shares | 106K USD notional · 0.001% of shares out |
| 30 Sep 2026 | Fails to deliver | Shares failed to deliver | 612 shares | 119K USD notional · 0.001% of shares out |
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS −0.68 USD | |
| 30 Sep 2026 | Financials | Total assets | 2.9B USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 2.1B USD | at period end |
| 25 Sep 2026 | Fails to deliver | Shares failed to deliver | 13,722 shares | 2.6M USD notional · 0.021% of shares out |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS 0.09 USD | |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS 0.15 USD | |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS 0.86 USD | |
| 31 Dec 2025 | Financials | Revenue | 738.3M USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | 48.9M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | 0.86 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS 0.26 USD | |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS 0.26 USD | |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS 0.10 USD | |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −0.46 USD |
Repligen (RGEN): frequently asked questions
What did Repligen shares close at?
Repligen closed at 168.52 USD on 5 Nov 2026, down 5.43% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Repligen’s market cap?
Repligen is worth 10.8B USD by market value as of 5 Nov 2026, which is the share price times the shares on issue from its SEC filings.
What is Repligen’s revenue?
Repligen reported revenue of 738.3M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have Repligen insiders bought or sold shares recently?
In the 90 days to 9 Nov 2026, Repligen insiders reported 5 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 12 Nov 2025, show no open-market purchase. A further 9 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders
Which funds own Repligen?
11 of the 45 funds we track reported a Repligen position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were Maverick Capital, Citadel Advisors and Balyasny Asset Management. See Funds
Have members of Congress traded Repligen?
Yes. 6 trades in Repligen appear in the congressional disclosures we hold; the latest is a sale by Lisa C. McClain (House, MI) dated 31 Oct 2025, filed 21 Nov 2025. Amounts are disclosed as ranges, and a filing can follow the trade by up to 45 days. See Congress
When did Repligen last report earnings?
Repligen last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.68 USD; no next date is announced in SEC filings yet. See Filings
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- House disclosuresU.S. House of Representatives financial disclosures
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings